Perrigo Company plc Loss Contingency, Receivable
Perrigo Company plc (PRGO) had Loss Contingency, Receivable of $48.40 million as of 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Commitment and Contingencies
us-gaap:LossContingencyReceivable · last filed 2026-08-05
- 2026-06-27: Loss Contingency, Receivable $48.40M.
- 2026-03-28: Loss Contingency, Receivable $35.20M.
- 2025-12-31: Loss Contingency, Receivable $26.90M.
- 2025-09-27: Loss Contingency, Receivable $18.90M.
| Period end | Loss Contingency, Receivable |
|---|---|
| 2026-06-27 | $48.40M 10-Q · filed 2026-08-05 |
| 2026-03-28 | $35.20M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $26.90M 10-K · filed 2026-02-26 |
| 2025-09-27 | $18.90M 10-Q · filed 2025-11-05 |
| 2025-06-28 | $17.90M 10-Q · filed 2025-08-06 |
| 2025-03-29 | $10.90M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $4.10M 10-K · filed 2025-02-28 |
| 2024-06-29 | $17.20M 10-Q · filed 2024-08-02 |
| 2024-03-30 | $25.50M 10-Q · filed 2024-05-07 |
| 2023-09-30 | $32.90M 10-Q · filed 2023-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |